Immuneering Corporation
6.25-0.24 (-3.7%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · IMRX · USD
Key Stats
Market Cap
395.24MP/E (TTM)
-Basic EPS (TTM)
-1.90Dividend Yield
0%Recent Filings
8-K
Immuneering launches $189M stock offering
Immuneering Corporation announced a public offering of 18,959,914 Class A common shares at $9.23 each on September 24, 2025, expecting $164.1 million in net proceeds, plus a concurrent $25 million private placement to Sanofi's Aventis Inc. for 2,708,559 shares at the same price, yielding $23.3 million net. Closings are set for September 26, 2025, subject to conditions. Funds will fuel preclinical and clinical development, extending the cash runway into 2029. Yet risks could alter outcomes.
8-K
Immuneering secures Sanofi funding
Immuneering Corporation inked a $25 million private placement with Sanofi's Aventis Inc., contingent on a public offering yielding at least $75 million gross proceeds by September 26, 2025. This bolsters funding for atebimetinib's Phase 3 pancreatic cancer trial, where interim Phase 2a data showed 86% nine-month overall survival and 53% progression-free survival in 34 patients, outpacing standard care estimates. Yet, cross-trial comparisons carry risks. Phase 3 kicks off by year-end.
8-K
Immuneering raises $25M in private placement
Immuneering Corporation announced a $25 million private placement on August 21, 2025, issuing 6.3 million shares (or pre-funded warrants) at $3.95 each, plus warrants for 2.8 million more shares at $5.50, closing around August 26. This bolsters the biotech's cash for advancing atebimetinib in pancreatic cancer trials, where early data showed 94% six-month survival versus 67% for standard care. Yet funding needs persist amid clinical risks.
8-K
Strong pancreatic cancer survival data
Immuneering Corporation reported Q2 2025 financials, highlighting exceptional 94% overall survival at 6 months in its Phase 2a trial of atebimetinib plus mGnP for first-line pancreatic cancer patients, far exceeding the standard 67% benchmark. The company secured a U.S. composition of matter patent for atebimetinib, extending exclusivity to 2042, while cash reserves dropped to $26.4 million from $36.1 million year-end, supporting operations into 2026. Updated OS and PFS data arrives Q3 2025; pivotal trial starts 2026. Patent bolsters long-term value, yet clinical risks persist.
10-Q
Q2 FY2025 results
Immuneering Corporation narrowed its Q2 net loss to $14.4M from $14.1M a year earlier, thanks to $0.3M lower employee costs and a $0.9M drop in IMM-6-415 spending, while atebimetinib expenses climbed $1.4M on trial progress. Operating expenses held steady at $14.8M year-over-year, with R&D flat at $10.5M and G&A up slightly to $4.3M. Cash burned $23.5M in H1, leaving $26.4M at quarter-end after a $13.7M ATM raise, funding into 2026 but raising going-concern doubts. Positive interim atebimetinib data showed 94% six-month OS in pancreatic cancer combos. Yet competition in oncology remains fierce.
ALT
Altimmune, Inc.
4.00-0.06
CUE
Cue Biopharma, Inc.
0.69-0.05
IMA
ImageneBio, Inc.
8.79+0.09
IMMX
Immix Biopharma, Inc.
3.72-0.18
IMNM
Immunome, Inc.
15.76-0.63
IMTX
Immatics N.V.
10.34-0.02
IMUX
Immunic, Inc.
0.80-0.04
MAIA
MAIA Biotechnology, Inc.
1.30-0.10
MRKR
Marker Therapeutics, Inc.
0.97-0.04
TIL
Instil Bio, Inc.
17.71-1.02